Drug
Verzistobart clinical trials
Also written INCAGN02390.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
6 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 2
Incyte Corporation (3) · University of Washington (1) · Incyte Biosciences International Sàrl (1) · University of Alabama at Birmingham (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses verzistobart is read from its arms, and is right about nine times in ten.
Testing it · 6
- Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedPhase 2Incyte Biosciences International SàrlNCT05287113Written as INCAGN02390
- Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell CarcinomaActive, not recruitingPhase 2University of WashingtonNCT06056895Written as Verzistobart
- Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.CompletedPhase 2Incyte CorporationNCT04463771Written as INCAGN02390
- An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial CarcinomaTerminatedPhase 2Incyte CorporationNCT04586244Written as INCAGN02390
- PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCLWithdrawnPhase 1University of Alabama at BirminghamNCT06290622Written as Retifanlimab, INCAGN02385, INCAGN02390
- A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesCompletedPhase 1Incyte CorporationNCT03652077Written as INCAGN02390
Given in every arm · 1 — verzistobart is usual care beside what is tested
Codes
What other systems call verzistobart · ClinicalTrials.gg INT017040
- UNII (FDA) KAC8QY6TMNVERZISTOBARTOne source FDA
- NCI Thesaurus C162625VerzistobartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KAC8QY6TMN | VERZISTOBART | One source FDA |
| NCI Thesaurus | C162625 | Verzistobart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.